XML 34 R14.htm IDEA: XBRL DOCUMENT v3.20.4
Major Customers and Concentration of Credit Risk
 12 Months Ended
Dec. 31, 2020
Risks and Uncertainties [Abstract]  
Major Customers and Concentration of Credit Risk Major Customers and Concentration of Credit Risk
 
Customer2020 Revenue% of Total
Revenue		2019 Revenue% of Total
Revenue		2018 Revenue% of Total
Revenue
ApolloBio$— — %$— — %$23,000,000 75 %
AstraZeneca170,587 2 3,194,877 78 6,850,424 23 
Advaccine5,000,000 68 — — — — 
Plumbline Life Sciences, Inc.1,370,396 18 — — — — 
All other, including affiliated entities870,237 12 917,053 22 631,473 2 
Total revenue$7,411,220 100 %1$4,111,930 100 %$30,481,897 100 %

During the years ended December 31, 2020, 2019 and 2018, the Company recognized revenue from various license and other agreements. As of December 31, 2020, $11.4 million, or 62%, and $7.1 million, or 38%, of the Company's accounts receivable was attributable to the DoD and Advaccine, respectively. As of December 31, 2019, $469,000, or 67%, and $161,000, or 23%, of the Company's accounts receivable was attributable to MCDC and AstraZeneca, respectively.
There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.